A Warning Letter Trend Surprise: Good In India, Bad In South Korea

A comparison of US FDA inspection and warning letter rates find India performs much better than China and South Korea.

Asia - Pacific
where asia-pacific drug quality issues are actually concentrated

The reason a lot of US Food and Drug Administration warning letters go to drug manufacturing facilities in India is not because the agency is more likely to find problems during inspections there, recent analysis by Govzilla shows.

It’s because the FDA conducts more inspections there.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance